ArticleJournal of gastroenterology2026
HOXC9 enhances cholesterol metabolism and malignancy in pancreatic ductal adenocarcinoma through ITGA10/FAK/PI3K/CREB-dependent HMGCR activation.
Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPancreatic ductal adenocarcinoma (PDAC) has a poor prognosis. Dysregulated cholesterol metabolism contributes to tumor progression, but its regulatory mechanisms in PDAC are unclear. This study explored the role and mechanism of homeobox C9 (HOXC9) in cholesterol regulation and PDAC development.
methodsHOXC9 was identified by bioinformatics as a key cholesterol metabolism gene in PDAC. Its expression was validated via qRT-PCR, Western blot, and immunohistochemistry, while cholesterol were measured using microassay and Filipin III staining. In vitro assays and subcutaneous tumor models in nude mice were used to assess its functional roles. RNA-seq, ChIP-qPCR, and dual-luciferase reporter assays explored molecular mechanisms.
resultsHOXC9 was identified as a key cholesterol metabolism-related transcription factor in PDAC. High-throughput data analysis based on TCGA databases further revealed that HOXC9 was highly expressed in PDAC tissues and associated with dismal prognosis. Clinically, HOXC9 upregulation correlates positively with tumor cholesterol, advanced stage, and reduced survival. Functionally, HOXC9 promotes PDAC cell proliferation, migration, and invasion in a cholesterol-dependent manner. In vivo, HOXC9 knockdown suppressed tumor growth and intratumoral cholesterol in nude mice, an effect reversible by high-cholesterol diet. Mechanistically, transcriptome sequencing highlighted the PI3K-Akt pathway as a key downstream target. HOXC9 transcriptionally activates ITGA10, which upregulates HMGCR via the FAK/PI3K/CREB, thereby driving cholesterol metabolism and tumor progression.
conclusionsHOXC9 may be a key transcriptional regulator of cholesterol metabolism in PDAC, promoting malignant progression by activating the ITGA10/FAK/PI3K/CREB to regulate HMGCR-mediated cholesterol synthesis. The essential role of the HOXC9-ITGA10-cholesterol axis in PDAC progression offers a novel potential target for therapy.
Indexed as
Identifiers
42283762What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.